Methotrexate subcutaneous injection - Nordic Group

Drug Profile

Methotrexate subcutaneous injection - Nordic Group

Alternative Names: Nordimet; Reditrex; Zlatal®

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nordic Group
  • Class Abortifacients; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Benzamides; Disease-modifying antirheumatics; Glutamates; Pterins; Small molecules
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Most Recent Events

  • 16 Nov 2016 Methotrexate subcutaneous injection licensed to Cumberland in USA
  • 18 Aug 2016 Launched for Rheumatoid arthritis in European Union (SC) after August 2016
  • 18 Aug 2016 Registered for Rheumatoid arthritis in European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top